The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
Subscribe To Our Newsletter & Stay Updated
